Decapeptyl
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TRELSTAR | — | 2000-06-15 | fda.gov ↗ |
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02908438 | Sep 2016 → Sep 2017 | — | Northwest Women's and Children's Hospital, Xi'an, Shaanxi | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05557604 | Feb 2021 → Feb 2024 overdue | prostate cancer | Regina Elena Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT00194792 | Aug 2005 → Jul 2011 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | University of Washington | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04356664 | Mar 2021 → Jun 2026 overdue | adenomyosis, endometriosis, female infertility | Hopital Foch | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06525155 | Jan 2024 → Feb 2025 overdue | endometriosis | Rumah Sakit Pusat Angkatan Darat Gatot Soebroto | Recruiting | No outcome recorded |
| Phase 3 | NCT05019846 | Sep 2021 → Dec 2025 overdue | prostate cancer | Marco Lorenzo Bonu | Recruiting | No outcome recorded |
| Phase 3 | NCT02862782 | Sep 2016 → Sep 2019 | — | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02048891 | Oct 2014 → Jan 2015 | infertility disorder | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 4 | NCT02749825 | Sep 2002 → May 2006 | prostate cancer | Pharmatech | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT03660813 | Jul 2018 → Aug 2021 | — | Sheba Medical Center | Completed | No outcome recorded |
| — | NCT02827656 | Aug 2016 → Aug 2017 | infertility disorder | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT02368964 | Feb 2015 → Jun 2020 | infertility disorder | Sheba Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 24 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03332797 Background | Nov 2017 → Jul 2027 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07142551 Background | Mar 2026 → Jun 2030 expected | castration-resistant prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT06922318 Background | Aug 2025 → Aug 2031 expected | castration-resistant prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT06059118 Background | Oct 2023 → Jan 2027 expected | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT03809000 Background | Apr 2019 → Apr 2023 overdue | prostate cancer | RTOG Foundation, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03311555 Background | Mar 2018 → Dec 2022 | prostate cancer | Andrew J. Armstrong, MD | Completed | No outcome recorded |
| Phase 2 | NCT02429999 Comparator | Apr 2015 → Oct 2016 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT02168062 Background | Jun 2014 → May 2018 | prostate adenocarcinoma | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 2 | NCT01790126 Comparator | Mar 2013 → Mar 2019 | prostate cancer | Aragon Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06282588 Background | Dec 2023 → Jul 2030 expected | prostate cancer | Cancer Research Antwerp | Recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04961996 Background | Aug 2021 → Aug 2025 overdue | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04537078 Comparator | Sep 2020 → Mar 2021 | female infertility | El Shatby University Hospital for Obstetrics and Gynecology | Completed | No outcome recorded |
| Phase 3 | NCT04064840 Comparator | Sep 2019 → Sep 2024 overdue | infertility disorder | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 3 | NCT02342197 Comparator | Jan → Dec 2011 | infertility disorder | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01888744 Comparator | Sep 2010 → Jun 2013 | infertility disorder | University Hospital Brussels | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT06739759 Comparator | Nov 2024 → Jun 2025 overdue | ovarian hyperstimulation syndrome | Aljazeera Hospital | Recruiting | No outcome recorded |
| — | NCT05838105 Comparator | Oct 2022 → Jan 2025 | — | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| — | NCT04749979 Comparator | Feb → Jun 2021 | infertility disorder | Aljazeera Hospital | Unknown | No outcome recorded |
| — | NCT02737800 Comparator | Apr 2016 → Aug 2017 | ovarian endometriosis | Kasr El Aini Hospital | Completed | No outcome recorded |
| — | NCT02346253 Background | Jan 2015 → Dec 2021 | prostate adenocarcinoma | Stanford University | Completed | No outcome recorded |
| — | NCT02144818 Comparator | Jan 2014 → Jul 2015 | ovarian dysfunction | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT01790282 Background | Mar 2013 → Dec 2014 | infertility disorder | Mansoura Integrated Fertility Center | Completed | No outcome recorded |
| — | NCT01389713 Comparator | Sep 2008 → Dec 2010 | infertility disorder | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Completed | No outcome recorded |
| — | NCT00542126 Comparator | Dec 2007 → Sep 2009 | — | Shaare Zedek Medical Center | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-06-12 | Ipsen | Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years ipsen.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decapeptyl | “GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.” NCT02908438 ↗21“ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.” NCT02048891 ↗ “daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle” NCT01389713 ↗ “Single intramuscular 0.1 mg decapeptyl are given on day of transfer” NCT01790282 ↗ “One or two intramuscular injections of Decapeptyl 3 mg” NCT04356664 ↗ “Day 3 after ET - Ovitrelle 125mcg + Decapeptyl 0.1mg” NCT05838105 ↗ “antagonist protocol with triggering by Decapeptyl” NCT06739759 ↗ “0.1 decapeptyl from day 21 in the previous cycle” NCT02429999 ↗ “GnRH agonist - Decapeptyl , hCG - Ovitrelle” NCT02368964 ↗ “Decapeptyl® 0,1 mg subcutaneously daily” NCT01888744 ↗ |
| Known as | Trelstar | “Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix...” NCT03311555 ↗6“Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout...” NCT06922318 ↗ “Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally” NCT01790126 ↗ “luteinizing hormone-releasing hormone (LHRH) agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix)” NCT06059118 ↗ “Trelstar®” NCT03809000 ↗ |
| Known as | Triptorelin Embonate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06525155 ↗ |
| Known as | triptorelin pamoate | “Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix...” NCT03311555 ↗5“The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according...” NCT03332797 ↗ “LHRH agonists may include, but are not limited to, leuprolide acetate, goserelin acetate, or triptorelin pamoate.” NCT04961996 ↗ |
| Action | Inhibit | “to inhibit endogenous testosterone production” NCT06922318 ↗ |
| Route | Intramuscular | “triptorelin pamoate intramuscularly (IM)” NCT00194792 ↗ |